Perimenopause Prescribing in 2026: Why Compounding Is the Missing Piece

Estrogen-based hormone replacement therapy prescribing has more than doubled since 2018. The most dramatic increase is in the perimenopause population: as of February 2026, 1 in 20 women aged 45–54 has an active estrogen-based HRT prescription, a 184% increase across the study period. Patch use has tripled. Vaginal cream use has quadrupled. The FDA’s removal of boxed warnings on HRT products last year accelerated a trend that was already well underway.

For prescribers, the clinical demand is clear. The operational challenge is that the FDA-approved HRT formulary doesn’t cover every patient—and the patients it doesn’t cover are arriving in numbers that compounding pharmacies were not built to handle through phone calls and fax machines.

Why the Perimenopause Wave Is Different

Earlier symptom recognition. The cultural shift toward recognizing and treating perimenopause—driven by patient advocacy, social media, and high-profile coverage—means women are presenting earlier, often in their late 30s and early 40s, with irregular cycles, vasomotor symptoms, sleep disruption, and mood changes. These patients often have fluctuating hormone levels rather than the flat postmenopausal profile, which makes fixed-dose commercial products a less precise fit.

Post-boxed-warning confidence. The FDA’s removal of the black box warning on HRT products—pointing to newer delivery methods and evolving safety evidence—has materially increased both prescriber willingness and patient demand. Clinicians who were reluctant to initiate HRT during the post-WHI era are now prescribing with more confidence, and patients are actively requesting it.

Supply chain fragility. The 2026 estrogen patch shortage exposed how concentrated the commercial HRT supply chain has become. When Bayer discontinued Climara and only three manufacturers remained for the majority of U.S. estradiol patches, any demand spike creates nationwide access problems. Prescribers who rely exclusively on commercial products are one shortage away from having no options for their patients.

The Compounding Formulary for Perimenopause

Compounded estradiol and Bi-Est. Bi-Est (a combination of estriol and estradiol, typically in an 80:20 ratio) remains the most commonly prescribed compounded estrogen preparation. It is available in transdermal creams, vaginal preparations, and sublingual troches. Compounding allows precise dose titration—starting at low doses for early perimenopause and increasing as the patient’s symptoms and labs dictate—without being locked into the fixed-dose increments of commercial products.

Micronized progesterone. The most commonly prescribed compounded progesterone form. Prometrium (the FDA-approved oral micronized progesterone) comes in 100 mg and 200 mg capsules. Compounding pharmacies prepare micronized progesterone in capsules, topical creams, vaginal inserts, and sublingual troches at custom doses—typically 25 mg to 400 mg—allowing prescribers to match the dose to the clinical scenario rather than the pharmacy shelf.

Testosterone for women. There is no FDA-approved testosterone product for women in the United States, despite strong evidence supporting low-dose testosterone for hypoactive sexual desire, energy, and musculoskeletal health in perimenopausal and postmenopausal women. Compounded testosterone creams (typically 0.5–2 mg daily) are the primary prescribing pathway. This is a compounding-only category.

DHEA. Compounded DHEA—both oral and vaginal—fills a gap for genitourinary symptoms and broader adrenal support. Intrarosa (prasterone) is the only FDA-approved vaginal DHEA product, but compounding offers dose flexibility and combination formulations that the single commercial product cannot.

Why the Prescribing Workflow Is the Bottleneck

The clinical knowledge exists. The formulations exist. The bottleneck is the workflow between prescriber and pharmacy.

When 5% of a practice’s prescriptions are compounded, that’s manageable. When 30–50% are compounded—as is common in menopause-focused practices—it’s a scaling crisis. eNavvi eliminates the parallel workflow. Prescribers access the full HRT compounding formulary—Bi-Est, progesterone, testosterone, DHEA—alongside FDA-approved medications from a single digital platform, with electronic prescriptions sent to PCAB-accredited pharmacies and transparent cash pricing visible before the script is sent.

The Perimenopause Prescribing Workflow That Scales

Browse eNavvi’s compounded HRT templates—Bi-Est, micronized progesterone, testosterone, DHEA—across PCAB-accredited pharmacies with transparent cash pricing. Free for prescribers. Electronic prescribing. No faxes.

Frequently Asked Questions

Q: Why has HRT prescribing increased so dramatically?

A: Estrogen-based HRT prescribing has more than doubled since 2018, driven by increased perimenopause recognition, cultural destigmatization, updated clinical guidelines, and the FDA’s removal of boxed warnings on HRT products. As of February 2026, 1 in 20 women aged 45–54 has an active estrogen-based HRT prescription.

Q: Is there an FDA-approved testosterone product for women?

A: No. Despite clinical evidence supporting low-dose testosterone for hypoactive sexual desire and other symptoms in perimenopausal and postmenopausal women, there is no FDA-approved testosterone product for women in the United States. Compounded testosterone creams from PCAB-accredited pharmacies are the primary prescribing pathway.

Q: What is Bi-Est and how is it prescribed?

A: Bi-Est is a compounded combination of estriol and estradiol, typically in an 80:20 ratio. It is available in transdermal creams, vaginal preparations, and sublingual troches. Bi-Est allows prescribers to provide a bioidentical estrogen preparation with dose flexibility not available in commercial fixed-dose products. It is prescribed through compounding pharmacies—platforms like eNavvi allow electronic prescribing to PCAB-accredited pharmacies with transparent pricing.